The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway
Qing Li(Tongji Hospital), Ming Xiang(Huazhong University of Science and Technology), Senlin Li(Huazhong University of Science and Technology), Cheng Tian(Huazhong University of Science and Technology), Huimin Yuan(Huazhong University of Science and Technology), Jialuo He(Washington State University), Ferdinando Nicoletti(University of Catania), Paolo Fagone(University of Catania), Yi Lu(Huazhong University of Science and Technology), Jian Yang(Kunming Institute of Zoology)
Cited by 26
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495